论文部分内容阅读
目的观察替米沙坦联合辛伐他汀对早期糖尿病肾病患者病情疗效的影响。方法将确诊的早期糖尿病肾病患者98例随机分为对照组和治疗组各49例,两组均给予降糖、抗凝等常规治疗,在此基础上对照组给予替米沙坦口服,治疗组给予替米沙坦联合辛伐他汀口服,治疗24周后对比两组相关指标。结果两组治疗后FBG、24hUMA、Scr、SBP、DBP、TC、TG均较治疗前明显下降,HDL-C较治疗前明显升高,且治疗组24hUMA、Scr、TC、TG、HDL-C等较对照组改善更明显,差异均有统计学意义(P<0.05);两组不良反应差异无统计学意义(P>0.05)。结论替米沙坦联合辛伐他汀能明显减少早期糖尿病肾病患者24h尿中白蛋白的含量,其对早期糖尿病肾病的进展能起到延缓作用。
Objective To observe the effect of telmisartan combined with simvastatin on patients with early diabetic nephropathy. Methods Ninety-eight patients diagnosed with early diabetic nephropathy were randomly divided into control group and treatment group (n = 49). Both groups were given conventional therapy such as hypoglycemic and anticoagulation. On the basis of this, the control group was given telmisartan orally and the treatment group Given telmisartan combined with simvastatin orally, after 24 weeks of treatment compared the two groups of related indicators. Results The levels of FBG, 24hUMA, Scr, SBP, DBP, TC, TG in the two groups were significantly lower than those before treatment, and HDL-C was significantly higher than those before treatment Compared with the control group, the improvement was more obvious, the differences were statistically significant (P <0.05). There was no significant difference in adverse reactions between the two groups (P> 0.05). Conclusion Telmisartan combined with simvastatin can significantly reduce urinary albumin in patients with early diabetic nephropathy 24 hours, which can delay the progress of early diabetic nephropathy.